Key result
Cryoballoon ablation for the initial treatment of symptomatic persistent atrial fibrillation achieved freedom from atrial arrhythmias in 81.8% of patients at 1 year and 61.7% at 2 years.
Why the study?
While cryoballoon ablation is established for PVI in paroxysmal AF, its strategy required evaluation in consecutive patients with persistent AF undergoing initial ablation.
Is cryoballoon ablation a safe and effective strategy for the initial ablation procedure in patients with persistent atrial fibrillation?
Observational (n=1,140)
No
Is cryoballoon ablation a safe and effective strategy for the initial ablation procedure in patients with persistent atrial fibrillation?
Cryoballoon ablation is a safe and effective initial strategy for pulmonary vein isolation in patients with persistent atrial fibrillation, offering reasonable long-term freedom from arrhythmias.
Answers are grounded in this paper and cite their sources.
Cryoballoon PVI feasible in persistent AF; hypothesis-generating and requires randomized trials before practice change.
Background: Cryoballoon ablation is established for pulmonary vein isolation (PVI) in paroxysmal atrial fibrillation (AF). The objective was to evaluate CBA strategy in consecutive patients with persistent AF in the initial AF ablation procedure. Material and Methods: Prospectively, patients with symptomatic persistent AF scheduled for AF ablation all underwent cryoballoon PVI. Technical enhancements, laboratory management, safety, single-procedure outcome, predictors of recurrence, and durability of PVI were evaluated. Results: From 2007 to 2020, a total of 1,140 patients with persistent AF, median age 68 years, underwent cryoballoon ablation (CBA). Median left atrial (LA) diameter was 45 mm (interquantile range, IQR, 8), and Congestive heart failure, Hypertension, Age ≥75 years (doubled), Diabetes mellitus, prior Stroke or TIA or thromboembolism (doubled), Vascular disease, Age 65 to 74 years, Sex category (CHA 2 DS 2 -VASc) score was 3. Acute isolation was achieved in 99.6% of the pulmonary veins by CBA. Median LA time and median dose area product decreased significantly over time ( p < 0.001). Major complications occurred in 17 (1.5%) patients including 2 (0.2%) stroke/transitory ischemic attack (TIA), 1 (0.1%) tamponade, relevant groin complications, 1 (0.1%) significant ASD, and 4 (0.4%) persistent phrenic nerve palsy (PNP). Transient PNP occurred in 66 (5.5%) patients. No atrio-esophageal fistula was documented. Five deaths (0.4%), unrelated to the procedure, occurred very late during follow-up. After initial CBA, arrhythmia recurrences occurred in 46.6% of the patients. Freedom from atrial arrhythmias at 1-, and 2-year was 81.8 and 61.7%, respectively. Independent predictors of recurrence were LA diameter, female sex, and use of the first cryoballoon generation. Repeat ablations due to recurrences were performed in 268 (23.5%) of the 1,140 patients. No pulmonary vein (PV) reconduction was found in 49.6% of the patients and 73.5% of PVs. This rate increased to 66.4% of the patients and 88% of PVs if an advanced cryoballoon was used in the first AF ablation procedure. Conclusion: Cryoballoon ablation for symptomatic persistent AF is a reasonable strategy in the initial AF ablation procedure.
No takes yet. Share an insight, caveat, or question.
Straube et al. (2021) conducted an observational in Symptomatic persistent atrial fibrillation (n=1,140). Cryoballoon ablation was evaluated on Freedom from any atrial arrhythmia recurrences (AF or atrial tachycardia) and off antiarrhythmic drugs following a 90-day blanking period. Cryoballoon ablation for the initial treatment of symptomatic persistent atrial fibrillation achieved freedom from atrial arrhythmias in 81.8% of patients at 1 year and 61.7% at 2 years.
Synapse has enriched 10 related papers. Consider them for comparative context: